###### Strengths and limitations of this study

-   Our study included a total of 26 648 male and female adults with no antihypertensive drugs usage, by far the largest study of its kind.

-   We evaluated the association between total homocysteine (tHcy) concentrations and systolic or diastolic blood levels, and examined the potential modifiers in the association among a general adult population.

-   As a cross-sectional study, we were not able to determine the causal relationship between tHcy and blood pressure levels.

Introduction {#s1}
============

Hypertension is one of the major risk factors for cardiovascular disease (CVD), chronic kidney disease (CKD) and peripheral arterial disease.[@R1] By 2025, the global number of adults with hypertension will be 1.56 billion.[@R3] A better understanding of the modifiable risk factors of hypertension is crucial for clinical decision-making and timely management, for it would lead to early detection and prevention, decreasing the huge burden of hypertension and its associated complications.

Previous studies have shown that total homocysteine (tHcy), an intermediate product in the metabolism of methionine, is a controllable risk factor for many chronic diseases, including CVD, stroke and CKD.[@R4] The Hordaland Homocysteine Study[@R8] and the Third National Health and Nutrition Examination Survey study[@R9] further found that there was a positive association between tHcy and blood pressure levels. Consistently, Li *et al* reported that hyperhomocysteinaemia was independently related to the elevated diastolic blood pressure (DBP).[@R10] Another study indicated that hyperhomocysteinaemia was significantly associated with the prevalence of hypertension in males, but not in females in the general adult population of rural Northeast China.[@R11] Recently, a meta-analysis of relevant randomised trials, including 7887 participants, also indicated that folic acid therapy was effective in reducing the blood pressure and tHcy levels among patients with hypertension and hyperhomocysteinaemia.[@R12] However, in the China Stroke Primary Prevention Trial (CSPPT), folic acid therapy had no obvious effect on blood pressures in 20 702 hypertensive participants.[@R13] In fact, Fakhrzadeh *et al* [@R14] and Dinavahi *et al* [@R15] found no significant association between tHcy and blood pressure levels. Sundström *et al* [@R16] found no obvious relationship of tHcy levels with hypertension incidence or blood pressure progression. These results indicate that the relationship of tHcy with blood pressure remains controversial. The possible explanations included the differences in study populations, sample size and the concomitant drugs or diseases within the study populations. More importantly, although it has been suggested that age, sex, body mass index (BMI), smoking, alcohol drinking, fruit and vegetable consumption and life styles may affect the tHcy and blood pressure levels,[@R17] whether these factors could modify the association between tHcy and blood pressure had not been thoroughly investigated in these previous studies.

Therefore, the present study aimed to evaluate the relation of tHcy concentrations with blood pressure levels, and examine the potential modifiers in the association among a general Chinese adult population.

Methods {#s2}
=======

Study participants {#s2a}
------------------

We conducted an epidemiological study for identification, education and register of the high-risk population with both hypertension and elevated tHcy within 21 communities in Lianyungang of Jiangsu province, China, from July 2016 to September 2016. We recruited from the community through open recruitment rather than a random selection. All participants provided written informed consent.

Eligible participants were men and women aged 35 years and older. The lowest age limit was defined as 35 years old in order to improve the recruitment rate of patients with hypertensive. The exclusion criteria were as follows: (1) individuals with severe mental disorders; (2) individuals with abnormal laboratory tests or clinical manifestations who were unsuitable to participate as judged by the investigators and (3) anyone unwilling to participate in the study.

Patient and public involvement {#s2b}
------------------------------

Patient and public involvement was taken into consideration during the whole study. We performed a pilot study to evaluate the feasibility of the project and invited the participants to provide comments. The staff collected the comments of the participants for discussing and further updating the questionnaires and research design. As we have collaborated with local medical institutions to create archives of the participants and established long-term cohorts, our findings are regularly disseminated to the participants and local residents by the local medical institutions.

Data collection and measurements {#s2c}
--------------------------------

Baseline data were collected by trained research staff according to standard operating procedure. Face-to-face interviews were conducted using a standardised questionnaire designed specifically for the present study, which included information on demographic characteristics, diet, lifestyle, history of disease and medication use. Anthropometric measurements, including height and weight, were taken using standard operating procedures. Height and weight were measured to the nearest 0.1 cm and 0.1 kg, respectively, with the subject wearing light clothing and no shoes. BMI was calculated as weight (kg)/height (m^2^).

Current smoking was defined as having smoked ≥1 cigarette per day or ≥18 packs in the past year. Current alcohol drinking was defined as drinking alcohol at least two times per week in the past year. Diabetes was defined as having a history of diabetes or currently undergoing glucose-lowering therapy. Hyperlipidaemia was defined as having a history of hyperlipidaemia or currently undergoing lipid-lowering therapy. CVD was defined as having a history of stroke, coronary heart disease or heart failure. The question about standard of living was phrased as follows: 'How is your standard of living?' and a choice of three responses was given as follows: bad, medium and good. The question about fruit and green vegetable consumption was phrased as follows: 'How much fruit and green vegetables do you eat (count the annually averaged weekly intake of fruits and green vegetables)?' and a choice of three responses regarding weekly intake was given as follows: \<500 g, 500--1500 g and ≥1500 g. The question about sleep quality was phrased as follows: 'How do you describe your sleep quality?' and a choice of three responses was given as follows: poor, medium and good. The question about sleep time was phrased as follows: 'How long do you sleep every night?' and a choice of three responses was given as follows: \<5, 5--8 and ≥8 hours.

Trained research staff obtained systolic blood pressure (SBP) and DBP measurements after subjects had been seated for 10 min, using a validated automatic digital sphygmomanometer (Omron HEM 705IT device; Omron Healthcare), with appropriately sized cuffs. Triplicate measurements on the same arm were taken, with 1--2 min between readings. Each patient's SBP and DBP were calculated as the mean of the three independent measures. Hypertension was defined as SBP ≥140 mm Hg and/or DBP ≥90 mm Hg.

Blood sample collection and laboratory methods {#s2d}
----------------------------------------------

A fasting vein blood sample was obtained from each subject. Serum or plasma samples were separated within 30 min of collection and stored at −80°C. Serum tHcy levels were determined using commercial kits (Homocysteine Assay Kit (Hcy); Ausa Pharmed, Shenzhen, China) by enzymatic assay according to standard procedures.

Statistical analysis {#s2e}
--------------------

Means (SD) and proportions were calculated for population characteristics by tHcy categories (\<10, 10 to \<15 and ≥15 μmol/L). Differences in population characteristics were compared using analysis of variance tests or χ^2^ tests, accordingly.

Hyperhomocysteinaemia has been defined as a tHcy concentration ≥10 µmol/L[@R17] or 15 μmol/L[@R19] in previous studies. Therefore, the clinical cut-off levels of tHcy were set at 10 and 15 µmol/L in our current study. Furthermore, to confirm the consistency of the results, multivariate linear regression models were performed to determine the associations between tHcy as a continuous variable, tHcy categories (\<10 (reference), 10 to \<15 and ≥15 μmol/L) based on the clinical definition or tHcy quartiles (Q1: \<10.1 (reference), Q2: 10.1 to \< 12.2, Q3: 12.2 to \< 14.9 and Q4: ≥14.9 μmol/L) and SBP or DBP levels. Consistently, multivariate logistic regression models were performed to determine the associations between tHcy as a continuous variable, tHcy categories (\<10 (reference), 10 to \< 15 and ≥15 μmol/L), or tHcy quartiles (Q1: \<10.1(reference), Q2: 10.1 to \< 12.2, Q3: 12.2 to \<14.9 and Q4: ≥14.9 μmol/L) and the prevalence of hypertension. All models were adjusted for age, sex, study communities, BMI, smoking and drinking status, living standard, fruit and vegetable consumption, sleep quality, history of diabetes, hyperlipidaemia and CVD. In the subgroup analyses, possible modifications of the association between tHcy and blood pressure were assessed for the variables, age (\<60, ≥60), sex (male, female), BMI (\<24, 24 to \<28, ≥28 kg/m^2^), current smoking (yes, no), current alcohol drinking (yes, no), living standard (good, medium, bad), fruit and vegetable consumption (\<500, 500 to \< 1500, ≥1500 g), sleep quality (good, medium and poor) and sleep time (\<5, 5 to \<8 and ≥8 hours). Interactions were examined by including interaction terms in the multivariable linear regression models. BMI was categorised as normal weight (\<24.0 kg/m^2^), overweight (24.0 to \<28.0 kg/m^2^) and obesity (≥28.0 kg/m^2^) based on the guidelines of the Chinese Ministry of Health.[@R20]

A two-tailed p\<0.05 was considered statistically significant in all analyses. All statistical analyses were performed by Empower(R) ([www.empowerstats.com](www.empowerstats.com), X&Y Solutions, Boston, Massachusetts, USA) and statistical package R V.3.4.2 (<http://www.r-project.org>).

Results {#s3}
=======

Baseline characteristics {#s3a}
------------------------

A total of 26 648 participants (9262 males and 17 386 females) with complete data on blood pressure and tHcy levels and with no antihypertensive drugs use were included in the final analysis. We speculated that the use of antihypertensive drugs may decrease the blood pressure and affect the association between tHcy and blood pressure levels. Therefore, these participants were excluded from the current analyses. A flow chart of the participants is shown in online [supplementary figure 1](#SP1){ref-type="supplementary-material"}.
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The participants on average were 57.9 (SD: 10.3) years old with a mean tHcy levels of 13.2 (6.1) μmol/L. The participants were divided into three groups based on their baseline tHcy concentrations (\<10, 10 to \<15 and ≥15 μmol/L). General characteristics of these three groups are presented in [table 1](#T1){ref-type="table"}. The tHcy concentrations were directly associated with age, male sex, smoking and alcohol drinking and was inversely associated with BMI.

###### 

Characteristics of the participants by tHcy categories (n=26 648)

  Variables                                 tHcy, μmol/L   P values                      
  ----------------------------------------- -------------- --------------- ------------- ---------
  N (%)                                     6483 (24.3)    13 689 (51.4)   6476 (24.3)   
  Age, year                                 54.4±9.5       57.8±9.7        61.7±10.9     \<0.001
  Sex, male (%)                             1338 (20.6)    4417 (32.3)     3507 (54.2)   \<0.001
  Body mass index, kg/m^2^                  24.9±3.8       24.9±3.6        24.7±3.7      \<0.001
  tHcy, μmol/L                              7.8±2.2        12.3±1.4        20.4±7.9      \<0.001
  Current smoking (%)                       597 (9.6)      1919 (14.7)     1482 (24.6)   \<0.001
  Current alcohol drinking (%)              719 (11.6)     2208 (16.9)     1513 (25.1)   \<0.001
  Self-reported hyperlipidaemia             370 (5.9)      798 (6.1)       378 (6.3)     0.745
  Self-reported diabetes mellitus           331 (5.3)      631 (4.8)       263 (4.4)     0.050
  Self-reported cardiovascular diseases     491 (7.9)      1320 (10.1)     867 (14.4)    \<0.001
  SBP, mm Hg                                126.7±16.1     129.1±16.1      131.9±16.2    \<0.001
  DBP, mm Hg                                80.7±11.6      82.0±12.1       84.1±12.7     \<0.001
  Medication use, n (%)                                                                  
   Lipid-lowering drugs                     38 (0.6)       50 (0.4)        30 (0.5)      0.084
   Glucose-lowering drugs                   183 (2.8)      365 (2.7)       129 (2.0)     0.004
  Living standards                          \<0.001                                      
   Good                                     734 (11.8)     1850 (14.2)     866 (14.4)    
   Medium                                   4835 (77.7)    10 046 (77.0)   4539 (75.4)   
   Bad                                      652 (10.5)     1149 (8.8)      613 (10.2)    
  Fruit and vegetable consumption, g/week   \<0.001                                      
   \<500                                    291 (4.7)      498 (3.8)       352 (5.8)     
   500--1500                                1465 (23.5)    3079 (23.6)     1498 (24.9)   
   ≥1500                                    4465 (71.8)    9468 (72.6)     4168 (69.3)   
  Sleep quality                             \<0.001                                      
   Good                                     2784 (44.7)    5821 (44.6)     2906 (48.3)   
   Medium                                   2266 (36.4)    4846 (37.1)     2141 (35.6)   
   Poor                                     1172 (18.8)    2396 (18.3)     974 (16.2)    
  Sleep time, hours                                                                      \<0.001
   \<5                                      476 (7.5)      1177 (8.8)      568 (9.1)     
   5--8                                     3843 (60.4)    8123 (60.8)     3591 (57.4)   
   ≥8                                       2043 (32.1)    4070 (30.4)     2099 (33.5)   

For continuous variables, values are presented as mean±SD.

DBP, diastolic blood pressure; SBP, systolic blood pressure; tHcy, total homocysteine.

Association between tHcy concentrations and blood pressure {#s3b}
----------------------------------------------------------

Overall, there was a positive association between tHcy concentrations and SBP or DBP levels (continuous variable). Each 5 μmol/L tHcy increment was associated with 0.45 mm Hg (95% CI 0.29 to 0.61 mm Hg) increase in SBP levels and 0.47 mm Hg (95% CI 0.35 to 0.59) increase in DBP levels ([figure 1](#F1){ref-type="fig"} and [table 2](#T2){ref-type="table"}). Compared with participants with tHcy \<10 μmol/L, significantly higher SBP levels were found in those with tHcy 10--15 μmol/L (adjusted β=0.80 mm Hg; 95% CI 0.32 to 1.28) or ≥15 μmol/L (adjusted β=1.79 mm Hg; 95% CI 1.20 to 2.37; p for trend \<0.001). Consistently, significantly higher DBP levels were found in participants with tHcy 10--15 μmol/L (adjusted β=0.86 mm Hg; 95% CI 0.49 to 1.22) or ≥15 μmol/L (adjusted β=2.01 mm Hg; 95% CI 1.57 to 2.46; p for trend \<0.001) as compared with those with tHcy \<10 μmol/L.

![The relationship of total homocysteine concentrations with SBP (A) and DBP (B) levels. Adjusted for age, sex, study communities, body mass index, smoking and drinking status, living standards, fruit and vegetable consumption, sleep quality, history of diabetes, hyperlipidaemia and cardiovascular disease. DBP, diastolic blood pressure; SBP, systolic blood pressure.](bmjopen-2017-021103f01){#F1}

###### 

The relationship of total homocysteine with SBP and DBP levels, and the prevalence of hypertension

  Total Homocysteine, μmol/L   N        Mean±SD      Unadjusted            Adjusted\*                         
  ---------------------------- -------- ------------ --------------------- ------------ --------------------- ---------
  SBP, mm Hg                                                                                                  
   Per 5 μmol/L increase       26 648   129.2±16.3   1.16 (1.00 to 1.32)   \<0.001      0.45 (0.29 to 0.61)   \<0.001
   Categories                                                                                                 
    \<10                       6483     126.7±16.1   Ref.                               Ref.                  
    10 to \<15                 13 689   129.1±16.1   2.43 (1.95 to 2.90)   \<0.001      0.80 (0.32 to 1.28)   0.001
    ≥15                        6476     131.9±16.2   5.26 (4.71 to 5.82)   \<0.001      1.79 (1.20 to 2.37)   \<0.001
   P for trend                                                             \<0.001                            \<0.001
  DBP, mm Hg                                                                                                  
   Per 5 μmol/L increase       26 648   82.2±12.2    0.86 (0.74 to 0.98)   \<0.001      0.47 (0.35 to 0.59)   \<0.001
   Categories                                                                                                 
    \<10                       6483     80.7±11.6    Ref.                               Ref.                  
    10 to \<15                 13 689   82.0±12.1    1.37 (1.01 to 1.73)   \<0.001      0.86 (0.49 to 1.22)   \<0.001
    ≥15                        6476     84.1±12.7    3.44 (3.02 to 3.86)   \<0.001      2.01 (1.57 to 2.46)   \<0.001
   P for trend                                                             \<0.001                            \<0.001

  Hypertension†            N        Events (%)    Unadjusted            Adjusted                         
  ------------------------ -------- ------------- --------------------- ---------- --------------------- ---------
   Per 5 μmol/L increase   26 648   8536 (32.0)   1.14 (1.12 to 1.17)   \<0.001    1.07 (1.04 to 1.09)   \<0.001
   Categories                                                                                            
    \<10                   6483     1700 (26.2)   Ref.                             Ref.                  
    10 to \<15             13 689   4296 (31.4)   1.29 (1.20 to 1.37)   \<0.001    1.12 (1.04 to 1.21)   0.003
    ≥15                    6476     2540 (39.2)   1.82 (1.69 to 1.96)   \<0.001    1.32 (1.21 to 1.44)   \<0.001
   P for trend                                                          \<0.001                          \<0.001

\*Adjusted for age, sex, study communities, body mass index, smoking and drinking status, living standards, fruit and vegetable consumption, sleep quality, history of diabetes, hyperlipidaemia and cardiovascular disease.

†Hypertension was defined as SBP ≥140 mm Hg and/or DBP ≥90 mm Hg.

DBP, diastolic blood pressure; SBP, systolic blood pressure.

Accordingly, the prevalence of hypertension (binary variables) increased with the increment tHcy (per 5 μmol/L increment: OR 1.07; 95% CI 1.04 to 1.09) (online [supplementary figure 2](#SP1){ref-type="supplementary-material"} and [table 2](#T2){ref-type="table"}). The prevalence of hypertension was higher in subjects with higher tHcy concentrations: 26.2% in the tHcy \<10 μmol/L group, 31.4% in the tHcy 10--15 μmol/L group and 39.2% in the tHcy ≥15 μmol/L group. Compared with those with tHcy \<10 μmol/L, the adjusted ORs were 1.12 (95% CI 1.04 to 1.21) and 1.32 (95% CI 1.21 to 1.44) for the tHcy 10--15 μmol/L group and the tHcy ≥15 µmol/L group, respectively (p for trend \<0.001, [table 2](#T2){ref-type="table"}).

Similarly, SBP and DBP levels and the prevalence of hypertension increased through the quartiles of tHcy concentrations as did the adjusted ORs (All p for trend \<0.001) ([figure 2](#F2){ref-type="fig"}).

![Systolic blood pressure (SBP) levels (**A**), diastolic blood pressure (DBP) levels (**B**) and the adjusted ORs of hypertension (**C**) by quartiles\* of total homocysteine (tHcy) concentrations†. \*tHcy quartiles: Q1:\<10.1 (reference group), Q2:10.1 to \<12.2, Q3: 12.2 to \<14.9 and Q4: ≥14.9 μmol/L. †Adjusted for age, sex, study communities, body mass index, smoking and drinking status, living standards, fruit and vegetable consumption, sleep quality, history of diabetes, hyperlipidaemia and cardiovascular disease.](bmjopen-2017-021103f02){#F2}

Stratified analyses by potential effect modifiers {#s3c}
-------------------------------------------------

Stratified analyses were performed to assess the association between tHcy and SBP ([figure 3](#F3){ref-type="fig"}) and DBP (online [supplementary figure 3](#SP1){ref-type="supplementary-material"}) levels in various subgroups. Alcohol drinking positively modified the association between tHcy and SBP (p for interaction=0.009) and DBP (p for interaction=0.067) levels. A stronger association between tHcy and SBP or DBP levels was found in current alcohol drinkers. Other variables, including age, sex, BMI, smoking, living standards, fruit and vegetable consumption, sleep quality and sleep time, did not significantly modify the relationship of tHcy with SBP or DBP levels.

![Stratified analyses by potential effect modifiers for the association between total homocysteine and systolic blood pressure levels. Adjusted for age, sex, study communities, body mass index (BMI), smoking and drinking status, living standards, fruit and vegetable consumption, sleep quality, history of diabetes, hyperlipidaemia and cardiovascular disease.](bmjopen-2017-021103f03){#F3}

Discussion {#s4}
==========

Typically, Chinese populations are characterised by elevated tHcy, a high prevalence of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation, and no dietary folic acid fortification, rendering the current study population best suitable for examining the association between tHcy and blood pressure levels.[@R21] Our study included a total of 26 648 male and female adults with no antihypertensive drugs usage, by far the largest study of its kind. Our study has provided some new insights. First, there was a significantly linear association between tHcy and SBP or DBP levels in the general population. Second, alcohol drinking was an important modifier for the association between tHcy and SBP or DBP levels.

MTHFR is the main regulatory enzyme for folate/homocysteine metabolism. Polymorphism of MTHFR 677C\>T leads to a reduction in enzyme activity, resulting in increased concentrations of plasma Hcy and lower levels of serum folate. MTHFR C677T polymorphism has been reported to be associated with hypertension or high blood pressure. In line with our results, the studies by Heifetz and Birk had shown that tHcy may contribute to the effect of MTHFR C677T genotypes on blood pressure levels.[@R24] More importantly, Saraswathy *et al* [@R25] also suggested that MTHFR 677TT genotype and elevated tHcy levels (even in the upper limits of the normal range of 5--15 μmol/L) are significantly associated with hypertension regardless of age and gender in a Northeastern population with East Asian ancestry.

There are several potential mechanisms by which increased tHcy could contribute to high blood pressure. Raised tHcy has been shown to be associated with increased oxidative stress, hypertrophy of vascular muscle and changes in DNA methylation.[@R26] Furthermore, tHcy may induce endothelial dysfunction via increased asymmetric dimethylarginine, increased inflammation and decreased bioavailability of endothelium-derived NO.[@R27] Higher tHcy could also activate metalloproteinase and induces collagen synthesis and causes imbalances of elastin/collagen ratio. More importantly, elevated tHcy promoted ACE activity that may lead to upregulation of angiotensin II and subsequently hypertension.[@R29]

Our data also showed that a stronger association between tHcy and SBP or DBP levels was found in current alcohol drinkers. There are several possible explanations. First, it has been reported that acetaldehyde, a production of ethanol metabolite, could inhibit homocysteine remethylation by affecting the methionine synthase.[@R30] Furthermore, previous studies have also suggested that alcohol consumption may lead to folate deficiency due to the malabsorption, and increased urinary excretion.[@R31] Additionally, alcohol drinkers usually had a significantly higher frequency of MTHFR C677T mutation.[@R32] Therefore, alcohol drinkers may experience more severe tHcy-related vascular damage, which could partly explain the stronger association between tHcy and blood pressure levels in the current alcohol drinkers seen in this study. However, the exact mechanisms regarding the relationship of tHcy and alcohol drinking with the blood pressure levels remain to be further investigated, and our findings also warrant further confirmation.

It has been reported that higher folate intake is associated with a lower incidence of hypertension as seen in both the Nurses' Health Study[@R33] and the Coronary Artery Risk Development in Young Adults study.[@R34] Williams *et al*,[@R35] van Dijk *et al* [@R36] and a recent meta-analysis[@R12] of relevant randomised trials among patients with hypertension and hyperhomocysteinaemia reported that tHcy lowering with folic acid therapy may reduce the blood pressure levels. Our previous study[@R37] also suggested that elevated tHcy concentration significantly decreased the antihypertensive effect of both short-term and long-term enalapril-based antihypertensive treatment. However, studies by Moens *et al*,[@R38] Doshi *et al* [@R39] and the CSPPT study[@R13] found no obvious effect between folic acid therapy and blood pressure levels. We speculate that the folic acid fortification of enriched cereal grain in North American countries effective since January 1998, and the concomitant use of antihypertensive drugs may possibly have modified the treatment effect in previous studies. Therefore, the power for detecting the beneficial effect of folic acid therapy on blood pressure may be limited in previous studies. A large-scale clinical trial is needed to further investigate and confirm the effect of tHcy lowering on blood pressure levels with and without the concomitant use of antihypertensive drugs.

Several potential concerns or limitations are worth mentioning. First, as a cross-sectional study, we were not able to determine the causal relationship between tHcy and blood pressure levels. Second, the participants in our current study were recruited from the community through open recruitment rather than a random sampling strategy, which may have affected the representativeness of the population. The generalisability of our findings to other populations remains to be explored. Third, we did not measure the tHcy-related genetic variants, and could not evaluate the possible role of these variants in our current study. Fourth, although diabetes and dyslipidaemia had been included in the analyses, we did not have the actual values for blood glucose and lipids. Fifth, some of the information in our study was taken by questionnaire and this information could be biased. However, these questionnaires had been validated, and been applied to numerous previous projects.[@R2] In addition, we did not follow the Diagnostic and Statistical Manual of Mental Disorders criteria for the categorisation of alcoholics. Due to these limitations, confirmation of our findings in an independent study is essential.

Conclusions {#s5}
===========

Serum tHcy concentrations were positively associated with both SBP and DBP levels in a general Chinese adult population. The association was stronger in current alcohol drinkers. Our findings raise the possibility that a better understanding of the mechanism by which elevated Hcy effects blood pressure levels, may help to improve hypertension prevention and control, a burgeoning concern in clinical and community settings.
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